Literature DB >> 16258650

Menstrual cycle worsening of epileptic seizures in women with symptomatic focal epilepsy.

Ana Carolina Belini Bazán1, Maria Augusta Montenegro, Fernando Cendes, Li Li Min, Carlos A M Guerreiro.   

Abstract

INTRODUCTION: Hormonal fluctuation is responsible for worsening of epileptic seizures during the menstrual cycle.
OBJECTIVE: To identify irregularities in the menstrual cycles of women with mesial temporal lobe epilepsy (MTLE) and extratemporal focal epilepsy (ETFE) and correlate the frequency of seizures during the menstrual cycles.
METHOD: We evaluated prospectively women in the menacme with MTLE and ETFE. Calendars were provided for these patients, and they were asked to mark their seizure frequency according to the menses. Calendars were reviewed in each routine medical appointment.
RESULTS: Thirty-nine patients with MTLE and 14 with ETFE were evaluated. We registered 211 cycles in the patients with MTLE and 49 in those with ETFE. Irregular menstrual cycles were found in 28 (28/39, 71.7%) patients with MTLE and 6 (6/14, 42.8%) with ETFE (p=0.052). Premenstrual seizure worsening was observed in 46 (21.8%) patients with MTLE and 9 (18.3%) with ETFE (p=0.596). Menstrual worsening was observed in 47 (22.2%) patients with MTLE and 15 (30.6%) with ETFE (p=0.217). Ovulatory worsening was observed in 36 (17%) patients with MTLE and 13 (26.5%) with ETFE (p=0,126). Catamenial worsening was observed in 58 (27.4%) of the patients with MTLE and in 17 (34.7%) of the patients with ETFE (p=0.315).
CONCLUSION: There was no difference between the group of patients with MTLE and ETFE regarding the frequency of irregular cycles and seizure worsening during the premenstrual, menstrual, catamenial or ovulatory periods.

Entities:  

Mesh:

Year:  2005        PMID: 16258650     DOI: 10.1590/s0004-282x2005000500006

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  16 in total

Review 1.  The influence of gonadal hormones on neuronal excitability, seizures, and epilepsy in the female.

Authors:  Helen E Scharfman; Neil J MacLusky
Journal:  Epilepsia       Date:  2006-09       Impact factor: 5.864

Review 2.  Neurosteroids: endogenous role in the human brain and therapeutic potentials.

Authors:  Doodipala Samba Reddy
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

3.  Clinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptives.

Authors:  Doodipala Samba Reddy
Journal:  Expert Rev Clin Pharmacol       Date:  2010-03-01       Impact factor: 5.045

4.  A mouse kindling model of perimenstrual catamenial epilepsy.

Authors:  Doodipala Samba Reddy; Jordan Gould; O Gangisetty
Journal:  J Pharmacol Exp Ther       Date:  2012-03-20       Impact factor: 4.030

Review 5.  Sex differences in the anticonvulsant activity of neurosteroids.

Authors:  Doodipala Samba Reddy
Journal:  J Neurosci Res       Date:  2017-01-02       Impact factor: 4.164

6.  Interictal spike frequency varies with ovarian cycle stage in a rat model of epilepsy.

Authors:  James D'Amour; Alejandra Magagna-Poveda; Jillian Moretto; Daniel Friedman; John J LaFrancois; Patrice Pearce; Andre A Fenton; Neil J MacLusky; Helen E Scharfman
Journal:  Exp Neurol       Date:  2015-04-10       Impact factor: 5.330

Review 7.  Neurosteroids and their role in sex-specific epilepsies.

Authors:  Doodipala Samba Reddy
Journal:  Neurobiol Dis       Date:  2014-06-21       Impact factor: 5.996

Review 8.  The role of neurosteroids in the pathophysiology and treatment of catamenial epilepsy.

Authors:  Doodipala Samba Reddy
Journal:  Epilepsy Res       Date:  2009-04-29       Impact factor: 3.045

Review 9.  Neurosteroid regulation of GABAA receptors: A role in catamenial epilepsy.

Authors:  Suchitra Joshi; Jaideep Kapur
Journal:  Brain Res       Date:  2018-02-23       Impact factor: 3.252

Review 10.  Neurosteroid replacement therapy for catamenial epilepsy.

Authors:  Doodipala S Reddy; Michael A Rogawski
Journal:  Neurotherapeutics       Date:  2009-04       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.